Column

2025.01.29

Today, we would like to introduce a paper published by our client using our Chronic Kidney Disease model.   In this paper, the authors reported an improved pathology, and analyzed the mechanism of the UUO-induced kidney fibrosis model by histological and gene expression analysis after the administration of their compounds.   About the UUO model…

READ MORE

2025.01.29

We would like to introduce about a newly established positive control – an ALK5 inhibitor – for our UUO-induced renal fibrosis model. This ALK5 inhibitor has an inhibitory effect on the TGF-beta/ALK5 signaling pathway, which plays a central role in renal fibrosis. Below is the result of fibrosis analysis from an ALK5 inhibitor study in…

READ MORE

2025.01.29

We would like to introduce our Adenine-induced nephropathy mouse model, a chronic kidney disease (CKD) model.   Chronic kidney disease (CKD) is a progressive loss in kidney function. Kidney function is measured by Glomerular Filtration Rate (GFR), and blood biomarker (Serum creatinine and BUN). Due to the continuous decline in kidney function, the condition of…

READ MORE

2025.01.29

We would like to introduce a non-invasive biomarkers for kidney disease models.          Urine NGAL levels in ADR model at Day28   Generally, eGFR is calculated using creatinine and is used to diagnose chronic kidney disease (CKD). However, when the effect on the kidney is weak, issues such as slow or no change are…

READ MORE

2025.01.29

We would like to introduce a chronic kidney disease (CKD) and our Adriamycin-induced nephropathy (ADR) mouse model.   Chronic kidney disease (CKD) is a progressive loss in kidney function. 1 in 10 people have some degree of kidney disease and every year millions die prematurely of complications related to CKD. About 1% of CKD patients…

READ MORE

2025.01.28

We would like to introduce the features of the STAMTM-HCC/IO+ model as a liver cancer model. For your reference, we hope you will also visit our special website at the URL below. https://www.smccro-lab.com/Immuno-oncology/en/   Liver cancer, primarily HCC, is the fourth most common cancer in the world (Huang DQ et al, Nature Reviews Gastroenterology &…

READ MORE

2025.01.28

We are excited to share new efficacy data for Etrasimod (VELSIPITY) in inflammatory bowel disease (IBD) mouse models. Etrasimod, a sphingosine 1-phosphate (S1P) receptor modulator, was approved on October 12, 2023, as an oral treatment for ulcerative colitis.   Building on our previous efficacy data for Mesalazine and Tacrolimus in IBD models, we have now…

READ MORE

2024.04.08

MASH Resmetirom STAM

As you may already know, the United States Food and Drug Administration (FDA) announced the approval of Rezdiffra (resmetirom), developed by Madrigal Pharmaceuticals, as the first treatment for MASH.   If you are developing a MASH treatment in this situation, you have the possibility to utilize the STAM™-HCC/IO+ model and get the most out of…

READ MORE

2024.03.21

If you are considering a drug evaluation study for liver cancer using a mouse model, our STAMTM-HCC/IO+ model best replicates the pathology and characteristics seen in human patients with liver cancer, which allows for the optimal evaluation of your compound’s efficacy. In addition to molecular targeted drugs such as lenvatinib and sorafenib, immune checkpoint inhibitors…

READ MORE

2024.03.19

On March 14th, industry-altering news was published. Do you know already what we are talking about? The United States Food and Drug Administration (FDA) announced their approval of Rezdiffra (resmetirom), developed by Madrigal Pharmaceuticals, as the first treatment for MASH. FDA approved first MASH treatment We are truly excited that a drug has been approved…

READ MORE